Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene +16 more
doaj +1 more source
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]
, 2016 BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C. +23 more
core +1 more source
Pharmaceutical Biology, 2020 Context Ligustrazine and valsartan are commonly used drugs in the treatment of cardiac and cardiovascular disease. Objective The interaction between ligustrazine and valsartan was studied to investigate the effect of ligustrazine on the pharmacokinetics ...
Yang Liu, Jiaqi Zhang, Di Wu, Liran Cui
doaj +1 more source
Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]
, 2016 Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L. +11 more
core +2 more sources
Searching for New Leads to Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents [PDF]
, 2018 The purpose of this investigation is to contribute to the development of new anticonvulsant drugs to treat patients with refractory epilepsy. We applied a virtual screening protocol that involved the search into molecular databases of new compounds and ...
Bruno Blanch, Luis Enrique +8 more
core +2 more sources
Frontiers in Cardiovascular Medicine, 2022 BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen +12 more
doaj +1 more source
Heterogeneous Pd catalysts as emulsifiers in Pickering emulsions for integrated multistep synthesis in flow chemistry [PDF]
, 2018 Within the “Compartmentalised Smart Factory” approach of the ONE-FLOW project the implementation of different catalysts in “compartments” provided by Pickering emulsions and their application in continuous flow is targeted.
Binks, Bernard P. +6 more
core +1 more source
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]
, 2016 Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva +17 more
core +1 more source
Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers
Journal of the American Heart Association, EarlyView., 2021 Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes +14 more
wiley +1 more source
Medičnì Perspektivi, 2018 The aim of the study: to evaluate the endothelial function of the vessels under the influence of combined antihypertensive therapy (valsartan 160 mg / amlodipine 5 mg vs valsartan 160 mg / hydrochlorothiazide 12,5 mg) in patients with CKD and subclinical
I. P. Garmish
doaj +1 more source